Adynxx receives FDA Fast Monitor designation for AYX1 Injection to treat chronic pain Adynxx, a clinical-stage pharmaceutical organization developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Medication Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain. ‘We will continue steadily to advance the development of AYX1 as quickly as possible for the benefit of patients who are in need of new treatment options for post-surgical discomfort.’ Related StoriesIdentifying obstructive coronary artery disease in females: an interview with Dr.General and administrative expenditures increased by $160,000 for the three months ended June 30, 2010 due to an increase in salary, trader relations expense and legal fees. Salaries and wages increased by around $38,000 because of the hiring of a fresh employee through the first quarter of fiscal 2010. Investor relations expenses increased by $48,000, because of increased IR-related actions performed by outside consultants, and legal costs increased by $43,000. As of 30 June, 2010, the Company acquired $457,000 in cash and cash equivalents and 48,224,320 common shares exceptional. The company raised an additional $2.65 million through the issuance of equity and warrants during July and August of 2010.
5.7 Million Pounds Of Beef Recalled A meat provider has expanded a surface beef recall greatly, which includes about 5 now.